WASHINGTON — Medical device maker Philips said Monday it will pay $1.1 billion to settle hundreds of personal injury lawsuits in the U.S. over its defective sleep apnea machines, which have been subject to a massive global recall. The Dutch manufacturer did not admit any fault and said it reached the agreement to resolve any uncertainty over the cases....

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Will nonprofit hospitals get a pass on noncompetes? No news was bigger last week than the Federal Trade Commission’s ban on noncompete agreements. If implemented, it would upend the competitive...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we learn there are some serious safety concerns around an experimental blood cancer drug from MorphoSys that has been the centerpiece of Novartis’ plan to acquire the company for $3 billion. Also, Doctors Without...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the...

Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion.  The all-cash deal values Diciphera at $25.60 per share, or a 75% premium to its Friday closing stock price. Deciphera markets a drug called Qinlock for patients with advanced gastrointestinal stromal tumors, or...

In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs of a study it ran for a tuberculosis treatment regimen and maintained this is the first time that expenses incurred for an individual clinical trial had been publicized. Moreover, the charity argued that its decision should help undercut a long-standing...